“Severe hypertriglyceridaemia”的搜索结果，显示 491-500 项，共有 9980 项

1. 外科 - 临床试验- 妙佑医疗国际

   ... severe residual upper-extremity motor impairment due to stroke. Testing Docetaxel-Cetuximab Or The Addition Of An Immunotherapy Drug, Atezolizumab, To The ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid ...

3. 外科 - 临床试验- 妙佑医疗国际

   ... severe residual upper-extremity motor impairment due to stroke. Testing Docetaxel-Cetuximab Or The Addition Of An Immunotherapy Drug, Atezolizumab, To The ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid ...

5. 放射科- 临床试验- 妙佑医疗国际

   VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with ...

7. 肾病和高血压- 临床试验- 妙佑医疗国际

   The purpose of this study is to determine whether patients with ADPKD present with abnormal levels of fumarate that correlates with disease severity and ...

8. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

   Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is ...

9. 外科 - 临床试验- 妙佑医疗国际

   The purpose of this study is to validate the use of a lymphatic imaging protocol to stage disease severity in patients with lymphedema and serve as a biomarker ...

10. 血液科- 临床试验- 妙佑医疗国际

    This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...